Lasmiditan succinate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for lasmiditan succinate and what is the scope of patent protection?
Lasmiditan succinate
is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Lasmiditan succinate has one hundred and eighteen patent family members in forty-four countries.
One supplier is listed for this compound.
Summary for lasmiditan succinate
| International Patents: | 118 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 17 |
| Patent Applications: | 1 |
| DailyMed Link: | lasmiditan succinate at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for lasmiditan succinate
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for lasmiditan succinate
Paragraph IV (Patent) Challenges for LASMIDITAN SUCCINATE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| REYVOW | Tablets | lasmiditan succinate | 50 mg and 100 mg | 211280 | 1 | 2024-01-31 |
US Patents and Regulatory Information for lasmiditan succinate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-003 | Dec 18, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-003 | Dec 18, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for lasmiditan succinate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | ⤷ Sign Up | ⤷ Sign Up |
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | ⤷ Sign Up | ⤷ Sign Up |
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-003 | Dec 18, 2020 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for lasmiditan succinate
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Poland | 372845 | Pirydynoilopiperydyny jako związki agonistyczne 5-HT1F (PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS) | ⤷ Sign Up |
| Colombia | 2019005290 | Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f | ⤷ Sign Up |
| South Korea | 20220019772 | 2,4,6-트리플루오로-N-[6--피리딘-2-일]-벤즈아미드 헤미숙시네이트의 대규모 제조를 위한 방법 및 중간체, 및 2,4,6-트리플루오로-N-[6--피리딘-2-일]-벤즈아미드 아세테이트의 제조 | ⤷ Sign Up |
| Ukraine | 77504 | PYRIDINOYLPIPERIDINS AS AGONISTS OF 5-HT1F | ⤷ Sign Up |
| Portugal | 3551617 | ⤷ Sign Up | |
| Poland | 210019 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
